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Abstract
The use of anti-tubercular therapy (ATT) along with anti-retroviral therapy (ART) in human immunodeficiency virus-
tuberculosis (HIV-TB) co-infected individuals could at times lead to paradoxical worsening due to an increase in the
inflammatory activity due to immune reconstitution inflammatory syndrome (IRIS) in the eye. This is characterized
by anterior and posterior segment inflammatory reactions which may occur in the form of serous retinal
detachment. We describe a case where the use of intravitreal anti-vascular endothelial growth factor (anti-VEGF)
agent led to resolution of the serous retinal detachment, which had failed to respond to other common modalities
of treatment.
An HIV-TB co-infected 18-year-old, male patient, who was started on ART and ATT developed IRIS in the form of
worsening of serous retinal detachment around a pre-existent asymptomatic tuberculoma. The patient was initially
treated with oral and topical steroids without a satisfactory response. Intravitreal bevacizumab was then tried for
this patient. Serial fundus photos and optical coherence tomography (OCT) taken before and after treatment
showed complete resolution of the serous retinal detachment with two doses of intravitreal bevacizumab.
Intravitreal anti-VEGF agents may have a role in the reversal of serous retinal detachment, which occurs as a part of
IRIS in HIV-tuberculosis co-infected individuals who have been started on anti-tubercular and anti-retroviral
therapies.
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Introduction
TB is one of the most common opportunistic infections
in HIV patients; however, ocular TB in HIV patients is
relatively rare. It can occur in the form of anterior or
posterior uveitis, most commonly in the form of
choroidal granulomas [1, 2]. We initiate anti-tubercular
therapy (ATT) and anti-retroviral therapy (ART), follow-
ing which most of the patients improve but some may de-
velop paradoxical reactions to this therapy. Paradoxical
reactions are defined as worsening of the disease after
starting of the appropriate therapy, which may be seen
with the use of either ATT or ART in both HIV positive
as well as negative individuals [3–5]. Topical and oral
steroids have been often used in the treatment of this
condition [6, 7].
We describe a case of serous retinal detachment that
developed around an asymptomatic, pre-existent, tuber-
culoma as a complication of paradoxical worsening of
IRIS, who was successfully treated with intravitreal
bevacizumab.
Case report
An HIV infected 18-year-old, male patient, with newly
diagnosed sputum smear negative pulmonary TB and
CD4 count of 22 cells/μl presented to us for routine
ophthalmic examination, without any ocular complaints.
The patient was not on ATT or ART at the time of
presentation. On examination, his visual acuity was 20/20
in both eyes, and a quiescent anterior chamber. The fun-
dus examination of the right eye showed a well-defined
choroidal tuberculoma of 1.5 disc diameter in size in the
posterior pole close to the inferior arcade, not involving
the fovea (Fig. 1a) and without vitritis or cystoid macular
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edema (Fig. 2a). The patient was started on ATT by pul-
monologist and 2 weeks later on ART. Five weeks later, he
came with complaints of decreased vision in the right eye.
His vision was 20/120 in the right eye and 20/20 in the left
eye. On examination of the right eye, the patient had mild
vitritis along with increase in the size and fluid around the
tuberculoma (Fig. 1b). Optical coherence tomography
(OCT) showed foveal serous retinal detachment with fluid
around the enlarged tuberculoma (Fig. 2b). FFA was done
which showed pooling of dye around the lesion in the pos-
terior pole. Internist opinion was sought, and the patient
was put on 1 mg/kg oral prednisolone acetate which was
given in a tapering dose over a period of 3 months. There
was no change in the lesion at 2 weeks. Since there was
no improvement, we decided to opt for another mode of
treatment in the form of anti-VEGF because of its ability
to decrease the vascular permeability. Vitreous tap was
taken during injection, which tested positive for TB-PCR.
After two doses of anti-VEGF, the patient had improved
visual acuity 20/40. The subretinal fluid had totally disap-
peared on OCT (Fig. 2c), and there was also a decrease in
the granuloma size (Fig. 1c). The patient has been followed
up for 12 months following the intravitreal bevacizumab in-
jection, and he has had no fluid or recurrence since then.
Fig. 1 Fundus photograph (a) of the right eye at presentation showing a well-defined, choroidal granuloma along the inferior arcade without any fluid
around the lesion, (b) increase in the size with appearance of surrounding fluid after starting of ATT and ART, (c) decrease in the size of lesion as well
as of fluid after anti-VEGF therapy
Fig. 2 Comparative optical coherence tomography scans passing through the granuloma at presentation (a), after starting ATT and ART with
massive fluid collection (b), and fluid resolution after anti-VEGF therapy (c)
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Discussion
Even though HIV infected individuals are at a very great
risk for systemic TB, ocular TB is relatively rare. Ocular
TB may cause features of anterior or posterior uveitis,
amongst which tubercle granuloma is the commonest
presentation [1, 2]. ATT is often initiated along with
ART to treat the disease, following which most of the
patients improve, but some patients may develop para-
doxical reactions to therapy [3]. This occurs as the body
is able to restore its capacity to mount an inflammatory
response against either infectious or non-infectious anti-
gens. The infectious agents implicated are mycobacteria,
varicella zoster, herpes viruses, and cytomegalovirus [4].
Ocular paradoxical reactions are associated with de-
crease in vision, floaters and vitritis, worsening of the ori-
ginal lesion, cystoid macular edema, development of new
lesions, and serous retinal detachment as was seen in our
patient. CD 4 T cell count has found not to be associated
with paradoxical reactions. Corticosteroids have been used
to treat the condition [5–7]; thus, we initially tried steroids
for him which failed to show any response in our patient.
Thus, we sought for an alternative therapy for him. One
report [8] has used intravitreal bevacizumab to correct
serous retinal detachment, and this also has shown to
cause regression of the tubercle granuloma size [9, 10].
Bevacizumab (Avastin; Genentech, Inc, South San
Francisco, CA, USA) is a humanized monoclonal antibody
against VEGF. We used intravitreal bevacizumab in two
doses at 1 month apart for our patient, and there was a
marked improvement in both the functional and anatomical
outcomes without any deterioration in the next 12 months
of follow-up period. In our case, reversal of the vascular per-
meability by intravitreal bevacizumab played a role in the re-
versal of the serous retinal detachment. Phase II trials of
bevacizumab in HIV patients state that in well-controlled
HIV patients, bevacizumab can be given safely, but data on
immune-deficient individuals is still awaited and so its use
in low CD4 counts remain questionable [11].
Primary treatment for ocular TB remains steroids with
ATT in non-HIV patients. But in HIV patients, ATT alone
is given without oral steroids and ART is started at 2- to
3-week interval. With the advent of ART, there has been
increased incidence of IRIS during the phase of immune
recovery. ATT has also solely shown to cause IRIS, even
in immune-competent patients. Treatment guidelines for
paradoxical IRIS syndrome in HIV are empirical. Our pa-
tient developed IRIS in the form of increased serous fluid
after being initiated on ATT and ART, and we document
its resolution with intravitreal bevacizumab.
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